Latest News

Some Australian-based companies are already assessing the risks of the 'Pelosi plan' with and contemplating whether they should delay the launch of new medicines to avoid the risk of withdrawal.

Australia needs to do more but "remains in reach" in the goal of eliminating hepatitis C by 2030, according to the general manager of Gilead Australia and New Zealand, Jaime McCoy.

No wasting time for many Mundiphama employees following the introduction of the company's new Paid Parental Leave Policy.

Bayer has launched a new partnership with 'Active Farmers' to support the delivery of fitness programs across rural Australia.

"This is an exciting outcome for osteoporosis prevention, as this is the first time osteoporosis has received the attention it deserves," said OA CEO Greg Lyubomirsky.

An official analysis of a new medicine pricing plan under consideration by the US Congress suggests it could halve the number of new medicines and ultimately undermine health outcomes.

The obvious and inevitable risk of the proposal is that companies will act to innoculate their larger and more lucrative market by not launching or significantly delaying the launch of new medicines in Australia. They may even be forced to consider removing already reimbursed medicines.

The November PBS schedule update includes some new medicines and a large number of 'new or amended items'.

The major parties have used the parliamentary debate over the proposed lowering of PBS safety net thresholds to prosecute their wider arguments on the program.

BioPharmaDispatch asked the Department to confirm it had provided this advice, specifically that 2,200 "medicines" had been added to the PBS.

Shadow minister Chris Bowen accused the government of "not really telling the truth" during an address to PharmaAus19 in Canberra yesterday.

“We are delighted to have someone of Mark’s experience leading PSA into its next stage,” said PSA national president, Associate Professor Chris Freeman.